Editas Medicine Inc

Editas Medicine is a clinical-stage biotechnology firm developing CRISPR–Cas9 gene-editing treatments. Editas is headquartered in Cambridge, Massachusetts, with offices in Boulder, Colorado. Editas was founded in the year 2013 under the name Gengine, Inc. by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners, and Flagship Ventures; the name was later changed to the current one. Editas with Allergan was the first to try to alter DNA within a person's body using CRISPR. Editas revised its agreement with Allergan's parent company, AbbVie, and recovered full rights to their portfolio of eye disease treatment medicines, including EDIT-101 for the treatment of LCA10. In Boulder, Colorado, the firm is constructing new chemical facilities.